Skip to main content
Azzam Ismail on Muck Rack

Azzam Ismail

As seen in: Drug and Therapeutics Bulletin, Journal of Clinical Pathology, Cell Reports, Diagnostic Histopathology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Azzam

Contact Azzam, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Molecular glioblastoma: high-grade malignancy with low-grade histomorphology

|
By Richard Digby, Oleg Anichtchik, Azzam Ismail
| Diagnostic Histopathology Verified
Keywords Glioma integrated diagnosis methylation profiling next generation sequencing Get full text access Log in, subscribe or purchase for full access. References 2. Horbinski, C. ∙ Berger, T. ∙ Packer, R.J. ... Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours Nat Rev Neurol. 2022; 18:515-529 3. Guo, X. ∙ Gu, L. ∙ Li, Y. ...
Open in Who Shared Issue with article?

Extracranial meningioma: a case of a rare tumour of the scalp

|
By Caroline Cartlidge, Caty Weeks, Azzam Ismail
| Diagnostic Histopathology Verified
References 1. Burger, P. ∙ Scheihauer, B.W. ∙ Vogel, F.C. Surgical pathology of nervous system and its coverings Churchill Livingston, Philadelphia, 2002 49-71 Intracranial menings 2. Rushing, E.J. ∙ Bouffard, J.P. ∙ McCall, S. ... Primary extracranial meningiomas: an analysis of 146 cases Head Neck Pathol. 2009; 3:116-130 3. Kim, T. ∙ Kim, J. ∙ Choi, J. ... Meningothelial hamartoma of the scalp Archives Craniofac Surg. 2020; 21:180 4. Kim, C.M. ∙ Jeon, Y.R. ∙ Kim, Y.J. ...
Open in Who Shared Issue with article?

ARHGAP12 and ARHGAP29 exert distinct regulatory effects on switching between two cell morphological states through GSK-3 activity

|
By Vinton Cheng, Philippa Vaughn-Beaucaire, Gary Shaw, Malte Kriegs, Alastair Droop, George Psakis, Michel Mittelbronn, Matt Humphries, Filomena Esteves, Josie Hayes, Julia V. Cockle, Sabine Knipp, Arndt Rohwedder, Azzam Ismail, Ola Rominiyi, Spencer J. Collis, Georgia Mavria, James Samarasekara, John E. Ladbury, Sophie Ketchen, Ruth Morton Verified, Sarah Fagan, Daniel Tams, Katie Myers Verified, Connor McGarrity-Cottrell, Mark J. Dunning, Marjorie Boissinot, George Michalopoulos, Sally Prior, Ewan Morrison, Susan Short, Sean E. Lawler, Anke Brüning-Richardson
| Cell Reports Verified
Main reagents The GSK-3 inhibitor bromoindirubin-3-oxime (BIO) (Selleckchem, Ely, UK; cat # S7198) in DMSO was prepared as predetermined working dilutions (5 μM) in the appropriate culture medium. The multi-targeted Src kinase inhibitor Dasatinib (Selleckchem, Ely, UK; cat # S1021) in DMSO was also prepared as predetermined working dilution (10 μM) in the appropriate culture medium.
Open in Who Shared Issue with article?
See all 11 articles